Antidepressants remain an important treatment option for millions of people living with depression, anxiety and other conditions. However, new UK safety measures are set to change how patients are informed about some of the potential risks associated with these widely prescribed medicines.
In October this year (2026), the Medicines and Healthcare products Regulatory Agency (MHRA) announced stronger safeguards following an extensive review of how antidepressant risks are communicated to patients and their families. The changes focus on two key areas, including suicidal thoughts and behaviours, and sexual dysfunction. These may persist after treatment has stopped.
As the measures are rolled out, the regulator’s message is clear, that patients need accessible, understandable information to make informed decisions about treatment, while healthcare professionals must ensure that important safety information is discussed rather than left unnoticed in a medicine leaflet.
Importantly, the announcement does not mean antidepressants have been withdrawn or that patients should stop taking them.
It reflects a renewed effort to improve transparency, communication and monitoring throughout treatment.
Why Are Antidepressant Safety Warnings Changing?
The MHRA’s review followed concerns raised by patients and families that existing patient information leaflets did not communicate certain risks clearly enough.
An expert working group convened by the Commission on Human Medicines examined the available evidence, clinical advice and experiences shared by people affected by these issues.
The review considered the communication of risks associated with 28 antidepressant medicines. Its recommendations were intended to make important information easier to find and understand, helping patients recognise potential problems and know when to seek support.
According to the MHRA, antidepressants remain effective medicines for depression and other conditions. For most people, when prescribed appropriately and used under clinical supervision, their benefits outweigh their risks.
The objective of the new measures is therefore not to discourage treatment, but to improve the quality of conversations between patients and healthcare professionals about its potential benefits, limitations and adverse effects.
Suicidal Thoughts And Behaviours
One of the central changes concerns the risk of suicidal thoughts and behaviours associated with antidepressant treatment.
The MHRA is introducing a more prominent boxed warning in patient information leaflets, directing readers to relevant safety information and sources of help. A patient card is also being introduced to reinforce key messages and make guidance easier to access when needed.
Healthcare professionals are being advised to discuss these risks when treatment begins, when an antidepressant dose changes, or at the patient’s next review. Patients should be encouraged to seek urgent medical attention if they experience new or worsening suicidal thoughts or feelings of suicidal intent, particularly after starting treatment or following a dose change.
This is especially important because the relationship between antidepressants, depression and suicidal behaviour is complex. Depression itself can involve suicidal thoughts, and the risks associated with treatment vary according to individual circumstances. A safety warning should not be interpreted as evidence that antidepressants cause suicidal behaviour in every patient.
Rather, the updated approach reinforces the importance of recognising changes in symptoms, maintaining appropriate follow-up and ensuring that patients know where to turn if their mental health deteriorates.
For clinicians, this means discussing warning signs in clear language, establishing suitable monitoring arrangements and making sure patients understand how to access urgent support.
Persistent Sexual Dysfunction
The second major focus is sexual dysfunction that may continue after antidepressant treatment ends.
Sexual side effects are a recognised concern with some antidepressants, particularly certain selective serotonin reuptake inhibitors (SSRIs). They can include reduced sexual desire, difficulty achieving orgasm, erectile difficulties and changes in genital sensation.
For some patients, these symptoms may persist after medication has been discontinued. The term post-SSRI sexual dysfunction (PSSD) is used by some patients and clinicians to describe persistent symptoms following SSRI treatment.
Under the new measures, patient information leaflets for certain antidepressants will be updated to include the term PSSD and better explain the possibility that symptoms may continue after treatment stops.
Attention to this is important as sexual side effects can affect relationships, quality of life and willingness to continue treatment. Patients may feel uncomfortable raising these concerns, particularly when appointments focus primarily on mood, anxiety or other symptoms.
Clearer information may help people recognise that sexual health is a legitimate part of treatment discussions. It can also encourage clinicians to ask about side effects proactively rather than relying on patients to raise concerns themselves.
What Will Change For Patients?
The MHRA’s announcement outlines several practical measures intended to strengthen communication.
First, patient information leaflets will include more prominent warnings about suicidal thoughts and behaviours. Leaflets for certain medicines will also provide clearer information about persistent sexual dysfunction.
Second, a patient safety card is being introduced to reinforce essential messages and help patients and carers identify when further assistance may be needed.
Third, an additional safety leaflet is being developed for distribution through healthcare professionals. It is intended to explain the benefits and risks of antidepressant treatment and support informed discussions about available options. The MHRA has indicated that this leaflet will become available for people starting treatment, as well as those already taking antidepressants.
The regulator is also working with organisations across the healthcare system to promote more consistent safety information in prescribing resources, professional guidance and patient communications.
Anyone concerned about side effects should arrange a discussion with their prescriber.
Antidepressants should not be stopped abruptly or changed without professional advice. Sudden discontinuation can cause withdrawal symptoms, and an appropriate reduction plan should be tailored to the individual.
Patients and healthcare professionals can also report suspected adverse drug reactions through the MHRA’s Yellow Card scheme, which helps regulators monitor medicine safety.
Ultimately, clearer warnings can help people make informed choices, recognise when they need support and participate more confidently in decisions about their mental health.